ImmuneBridge Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $7.7M

  • Investors
  • 16

ImmuneBridge General Information

Description

Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. The company's immunotherapies utilize proprietary expansion technology to amplify cord blood-derived immune stem cells while maintaining immune multipotency, offering a diverse and consistent cellular source, enabling progenitors with cellular pharmacopeia, and dealing with oncology treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2122 Bryant Street
  • San Francisco, CA 94110
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2122 Bryant Street
  • San Francisco, CA 94110
  • United States
+1 (415)

ImmuneBridge Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmuneBridge Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 24-Mar-2026 $7.7M Completed Generating Revenue
2. Accelerator/Incubator 16-Oct-2025 Completed Generating Revenue
1. Seed Round 09-Jan-2023 $12M $12M Completed Generating Revenue
To view ImmuneBridge’s complete valuation and funding history, request access »

ImmuneBridge Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed I
Seed I-B
Seed I-A 41,041,499 $0.000100 8% $0.05 $0.05 1x $0.05 10.75%
Seed 28,958,501 $0.000100 8% $0.07 $0.07 1x $0.07 0%
To view ImmuneBridge’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ImmuneBridge Patents

ImmuneBridge Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3138280-A1 Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole Pending 01-May-2019
EP-3962474-A1 Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole Inactive 01-May-2019
EP-3962474-A4 Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole Inactive 01-May-2019
US-20220378740-A1 Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole Inactive 01-May-2019
WO-2020223383-A1 Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole Inactive 01-May-2019 A61K31/403
To view ImmuneBridge’s complete patent history, request access »

ImmuneBridge Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmuneBridge Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Immortal Dragons Venture Capital Minority
LongGame Ventures Venture Capital Minority
Sand Hill Angels Angel Group Minority
T.Rx Capital Venture Capital Minority
Endless Frontier Labs Accelerator/Incubator Minority
You’re viewing 5 of 16 investors. Get the full list »

ImmuneBridge FAQs

  • When was ImmuneBridge founded?

    ImmuneBridge was founded in 2018.

  • Where is ImmuneBridge headquartered?

    ImmuneBridge is headquartered in San Francisco, CA.

  • What is the size of ImmuneBridge?

    ImmuneBridge has 16 total employees.

  • What industry is ImmuneBridge in?

    ImmuneBridge’s primary industry is Drug Discovery.

  • Is ImmuneBridge a private or public company?

    ImmuneBridge is a Private company.

  • What is ImmuneBridge’s current revenue?

    The current revenue for ImmuneBridge is .

  • How much funding has ImmuneBridge raised over time?

    ImmuneBridge has raised $19.7M.

  • Who are ImmuneBridge’s investors?

    Immortal Dragons, LongGame Ventures, Sand Hill Angels, T.Rx Capital, and Endless Frontier Labs are 5 of 16 investors who have invested in ImmuneBridge.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process